ArticleCellular oncology (Dordrecht, Netherlands)2026
The O-GlcNAc modification of PRRC2C at S2238 promotes SG formation and nasopharyngeal carcinoma metastasis.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeMetastasis remains the leading cause of mortality in patients with nasopharyngeal carcinoma (NPC), yet its precise mechanism has not been fully elucidated.
methodsIn this study, we established high metastatic (HM) and low metastatic (LM) sublines of NPC cells using the Transwell system, aiming to systematically investigate the metabolic reprogramming events that occur during NPC metastasis.
resultsMetabolomics sequencing results revealed that HM NPC cells have undergone metabolic profile remodeling, leading to increased levels of O-linked N-acetylglucosamine (O-GlcNAc) modification substrates UDP-GlcNAc and UDP-GalNAc, consequently, HM cells exhibited a significantly higher global O-GlcNAc modification level than LM cells. Through the construction of OGT-overexpressing cells and O-GlcNAc modification sequencing, we identified a significant elevation in the O-GlcNAcylation level of Proline-Rich Coiled-Coil 2 C (PRRC2C), a protein associated with stress granule (SG) formation. By transfecting PRRC2C WT and PRRC2C S2238A (serine 2238-to-alanine substitution) plasmids, we mimicked the characteristics of HM and LM cells and found that the O-GlcNAc modification of PRRC2C at S2238 site could promote the formation of SG at mitochondrial platform. Mechanistically, NPC cells transfected with the PRRC2C S2238A plasmids maintained mitochondrial functional homeostasis, evidenced by intact mitochondrial membrane potential and balanced mitochondrial dynamics compared to PRRC2C WT cells. In the nude mice orthotopic transplantation model, the use of epigallocatechin gallate (EGCG) could modulate the metastatic potential of HM cells via the inhibition of SGs.
conclusionCollectively, this study identifies targeting O-GlcNAcylation of PRRC2C at S2238 and SG formation as a promising therapeutic strategy for patients with metastatic NPC. REGISTRY AND THE REGISTRATION NO. OF THE STUDY/TRIAL: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.